UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________ FORM 20-F ________________________ (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR o SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report __________ Commission File Number: 001-39777 ________________________ NANOBIOTIX S.A. (Exact name of registrant as specified ...

Nanobiotix S.A. (NASDAQ:NBTX) Q3 2022 Earnings Call Transcript November 10, 2022 8:00 AM ET Company Participants Kate Mcneil - Senior Vice President, Investor Relations Laurent Levy - Co-Founder & Chief Executive Officer Bart Van Rhijn - Chief Financial Officer Conference Call Participants Mike DiFiore - Evercore Cl??ment Bassat - BNP Paribas Kate Mcneil Thank you, operator. Good afternoon and good morning, and welcome to Nanobiotix Conference Call to discuss our Third Quarter 2022 Financial and Operational ...

Nanobiotix S.A (NASDAQ:NBTX) Q2 2022 Earnings Conference Call September 29, 2022 8:00 AM ET Company Participants Laurent Levy - Co-Founder, CEO Bart Van Rhijn - CFO Kate McNeil - IR Conference Call Participants Jon Miller - Evercore Suzanne van Voorthuizen - Kempen Kate McNeil Good afternoon and good morning. And welcome to Nanobiotix Conference Call to discuss our First Half 2022 Financial and Operational results. Joining me in the call today, are Laurent Levy, co-Founder and Chief Executive Officer and Ba ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________ FORM 6-K ________________________ REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 28, 2022 Commission File Number: 001-39777 ________________________ NANOBIOTIX S.A. (Exact name of registrant as specified in its charter) _________________________ Nanobiotix S.A. 60 rue de Wattignies 75012 Paris, France (Address of principal ex ...

Nanobiotix S.A. (NASDAQ:NBTX) Q1 2022 Earnings Conference Call May 19, 2022 8:00 AM ET Company Participants Kate McNeil ??? Senior Vice President, Investor Relations Laurent Levy ??? Co-Founder and Chief Executive Officer Bart Van Rhijn ??? Chief Financial Officer Conference Call Participants Lucy Codrington ??? Jefferies Michael DiFiore ??? Evercore Cl??ment Bassat ??? Portzamparc RK Swayampakula ??? H.C. Wainwright Fr??d??ric Gomez ??? Pharmium Securities Operator Good day, and thank you for standing by. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________ FORM 20-F ________________________ (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended December, 31 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from __________ to _ ...

Nanobiotix S.A. (NASDAQ:NBTX) Q4 2021 Earnings Conference Call March 31, 2022 8:00 AM ET Company Participants Kate McNeil - Senior Vice President, Investor Relations Laurent Levy - Co-Founder & Chief Executive Officer Bart Van Rhijn - Chief Financial Officer Conference Call Participants Jonathan Miller - Evercore ISI Operator Ladies and gentlemen, thank you for standing by and welcome to Nanobiotix 2021 Full Year Corporate and Financial Update. At this time, all participants are in listen-only mode. After t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________ FORM 20-F ________________________ (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended December, 31 2020 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from __________ to _ ...